ArticleKidney international reports2023

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.

Jicheng Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.